Grand Pharmaceutical Group 과거 수익 실적

과거 기준 확인 2/6

Grand Pharmaceutical Group은 연평균 12.9%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 수입이 증가했으며, 연간 4.3%였습니다. 매출은 연평균 12.8%의 비율로 증가했습니다. Grand Pharmaceutical Group의 자기자본이익률은 15.3%이고 순이익률은 22.7%입니다.

주요 정보

12.9%

수익 성장률

11.5%

EPS 성장률

Pharmaceuticals 산업 성장	5.6%
매출 성장률	12.8%
자기자본 수익률	15.3%
순이익	22.7%
최근 수익 업데이트	30 Jun 2024

최근 과거 실적 업데이트

Recent updates

Grand Pharmaceutical Group Limited (HKG:512) Looks Inexpensive But Perhaps Not Attractive Enough

Sep 19

Grand Pharmaceutical Group (HKG:512) Is Paying Out A Larger Dividend Than Last Year

Jun 05

Market Participants Recognise Grand Pharmaceutical Group Limited's (HKG:512) Earnings

May 22

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Apr 25

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Mar 25

If You Like EPS Growth Then Check Out Grand Pharmaceutical Group (HKG:512) Before It's Too Late

Jan 24

These 4 Measures Indicate That Grand Pharmaceutical Group (HKG:512) Is Using Debt Safely

Dec 13

Grand Pharmaceutical Group Limited's (HKG:512) Intrinsic Value Is Potentially 45% Above Its Share Price

Nov 27

With EPS Growth And More, China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Is Interesting

Oct 25

China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Seems To Use Debt Rather Sparingly

Sep 01

Do China Grand Pharmaceutical and Healthcare Holdings's (HKG:512) Earnings Warrant Your Attention?

Jul 12

수익 및 비용 분석

Grand Pharmaceutical Group 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

SEHK:512 수익, 비용 및 수입 (HKD Millions )
날짜	수익	수익	G+A 비용
30 Jun 24	10,587	2,409	3,744
31 Mar 24	10,558	2,144	3,802
31 Dec 23	10,530	1,880	3,860
30 Sep 23	10,434	2,139	3,822
30 Jun 23	10,339	2,398	3,783
31 Mar 23	9,951	2,239	3,579
31 Dec 22	9,562	2,079	3,374
30 Sep 22	9,403	1,995	3,386
30 Jun 22	9,244	1,910	3,399
31 Mar 22	8,921	2,156	3,359
31 Dec 21	8,598	2,403	3,319
30 Sep 21	8,131	2,340	3,223
30 Jun 21	7,664	2,277	3,126
31 Mar 21	7,008	2,035	2,836
31 Dec 20	6,353	1,793	2,545
30 Sep 20	6,306	1,558	2,534
30 Jun 20	6,259	1,323	2,523
31 Mar 20	6,425	1,237	2,686
31 Dec 19	6,591	1,151	2,849
30 Sep 19	6,450	1,048	2,688
30 Jun 19	6,309	944	2,526
31 Mar 19	6,134	828	2,419
31 Dec 18	5,958	713	2,312
30 Sep 18	5,845	642	2,364
30 Jun 18	5,732	570	2,415
31 Mar 18	5,251	516	2,141
31 Dec 17	4,771	461	1,867
30 Sep 17	4,480	413	1,728
30 Jun 17	4,190	364	1,590
31 Mar 17	3,943	317	1,457
31 Dec 16	3,696	269	1,324
30 Sep 16	3,573	241	1,245
30 Jun 16	3,450	213	1,167
31 Mar 16	3,348	197	1,119
31 Dec 15	3,246	181	1,071
30 Sep 15	3,158	187	1,021
30 Jun 15	3,071	194	971
31 Mar 15	3,097	185	976
31 Dec 14	3,122	175	981
30 Sep 14	3,040	150	932
30 Jun 14	2,958	126	884
31 Mar 14	2,808	113	828

양질의 수익: 512 은 높은 수익을 보유하고 있습니다.

이익 마진 증가: 512 의 현재 순이익 이익률 (22.7%) 작년보다 낮습니다 (23.2%).

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: 512 의 수입은 지난 5년 동안 매년 12.9% 씩 증가했습니다.

성장 가속화: 지난 1년간 512 의 수익 증가율( 0.4% )은 5년 평균( 12.9% 보다 낮습니다. 년도).

수익 대 산업: 지난 1년간 512 수익 성장( 0.4% )은 Pharmaceuticals 업계 9.4% 능가하지 못했습니다. 9.4%.

자기자본 수익률

높은 ROE: 512 의 자본 수익률( 15.3% )은 낮음으로 간주됩니다.

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2025/02/06 07:58
장 마감 주가	2025/02/06 00:00
수익	2024/06/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처는 미국 증권의 예를 사용했습니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 Github에서 확인할 수 있습니다.

애널리스트 출처

Grand Pharmaceutical Group Limited 7 애널리스트 중 4 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Yanyin Zhu	China International Capital Corporation Limited
Xiao Wei Lin	Everbright Securities Co. Ltd.
Yiling Chen	Guosen Securities Co., Ltd.

Grand Pharmaceutical Group 과거 수익 실적

과거 기준 확인 2/6

주요 정보

최근 과거 실적 업데이트

First half 2024 earnings released: EPS: HK$0.44 (vs HK$0.29 in 1H 2023)

First half 2024 earnings released: EPS: HK$0.44 (vs HK$0.29 in 1H 2023)

Grand Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 19, 2024

Full year 2023 earnings: EPS misses analyst expectations

Grand Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 19, 2024

First half 2023 earnings released: EPS: HK$0.29 (vs HK$0.20 in 1H 2022)

Recent updates

Grand Pharmaceutical Group Limited Submits New Drug Application for the Global Innovative Product GPN01768 to the National Medical Products Administration of the People's Republic of China

Grand Pharmaceutical Group Limited's Global Innovative Intravascular Dual-Mode Imaging System NovasyNC Receives Registration Certificate for Medical Device by National Medical Products Administration of the People's Republic of China

Telix Pharmaceuticals Limited and Grand Pharmaceutical Group Limited Announces First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients

Grand Pharmaceutical Group Limited and Nanjing Kainite Medical Technology Company Limited Announce First Adjustable Intracranial Stent Retriever Product Produce in China Approve for Commercialization by NMPA

National Medical Products Administration Accepts Grand Pharmaceutical Group Limited's Phase III Clinical Study Application of ITM-11

Investor sentiment improves as stock rises 15%

First half 2024 earnings released: EPS: HK$0.44 (vs HK$0.29 in 1H 2023)

Grand Pharmaceutical Group Limited (HKG:512) Looks Inexpensive But Perhaps Not Attractive Enough

Grand Pharmaceutical Group Limited Appoints Lam Chit Yee Jessica as Executive Director

First half 2024 earnings released: EPS: HK$0.44 (vs HK$0.29 in 1H 2023)

Grand Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2024

Grand Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 19, 2024

Grand Pharmaceutical Group Limited Announces Executive Changes

Executive Chairman recently bought HK$526k worth of stock

Grand Pharmaceutical Group Limited Announces the Phase I Clinical Study Conducted in China of the Groups Global Innovative Ophthalmic Drug Gpn00884 Has Completed the First Patient Enrollment

Grand Pharmaceutical Group (HKG:512) Is Paying Out A Larger Dividend Than Last Year

Grand Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2023

Upcoming dividend of HK$0.26 per share

Executive Chairman recently bought HK$271k worth of stock

Market Participants Recognise Grand Pharmaceutical Group Limited's (HKG:512) Earnings

Executive Chairman recently bought HK$489k worth of stock

Grand Pharmaceutical Group Limited, Annual General Meeting, Jun 04, 2024

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Executive Chairman recently bought HK$371k worth of stock

Executive Chairman recently bought HK$243k worth of stock

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Dividend increased to HK$0.26

Executive Chairman recently bought HK$381k worth of stock

Grand Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 27 June 2024

Full year 2023 earnings: EPS misses analyst expectations

Grand Pharmaceutical Group Limited Proposes Dividend for the Year Ended 31 December 2023, Payable on 27 June 2024

Grand Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 19, 2024

Grand Pharmaceutical Group Limited Announces Update on Global Innovative Ophthalmic Drug GPN00884

Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application in China of the Group's Global Innovative Ophthalmic Drug GPN00884 Was Accepted by NMPA

Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application of ARC01 (A002)

Grand Pharmaceutical Group Limited Announces Phase III Clinical Trial in China of the Groups Global Innovative Ophthalmic Drug GPN00833 Has Completed the First Patient Enrollment and Dosing

We Think Grand Pharmaceutical Group (HKG:512) Can Stay On Top Of Its Debt

Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching

Grand Pharmaceutical Group Limited Announces Phase III Clinical Study in China of the Group's Global Innovation Drug RYaltris® Compound Nasal Spray Has Completed and Successfully Met Primary Endpoint

Grand Pharmaceutical Group Limited Announces That the Phase I Clinical Trial of Apad, A Global Innovative Drug Independently Developed by the Group for the Treatment of Sepsis, Has Completed First Subject Enrollment and Dosing Approved Recently

First half 2023 earnings released: EPS: HK$0.29 (vs HK$0.20 in 1H 2022)

Grand Pharmaceutical Group Limited Announces New Mra Drug of the Group Eplerenone Tablets Was Granted Drug Registration Certificate

Grand Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 10, 2023

Grand Pharmaceutical Group Limited Announces Approval by National Medical Products Administration to Conduct Phase II Clinical Study in China

Less than half of directors are independent

Grand Pharmaceutical Group Limited Appoints Yang Guang as an Executive Director

Grand Pharmaceutical Group Limited Announces Resignation of Niu Zhanqi as Executive Director

Less than half of directors are independent

Grand Pharmaceutical Group's (HKG:512) Dividend Will Be Increased To HK$0.14

Grand Pharmaceutical Group Limited Announces Board Changes

Upcoming dividend of HK$0.14 per share at 2.9% yield

Grand Pharmaceutical Group Limited Announces the Multicenter Phase III Clinical Trial of Ryaltris Compound Nasal Spray

Is Grand Pharmaceutical Group (HKG:512) A Risky Investment?

Full year 2022 earnings released: EPS: HK$0.59 (vs HK$0.68 in FY 2021)

National Medical Products Administration of the People's Republic of China Accepts Grand Pharmaceutical Group Limited's Investigational New Drug Applications of the Group Three Innovative Products in China

Grand Pharmaceutical Group Limited Conducts Clinical Trials of its Innovative Oral Small Molecule 3Cl Protease Inhibitor GS221 Against COVID-19

Investor sentiment improved over the past week

Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly

Less than half of directors are independent

Investor sentiment improved over the past week

Grand Pharmaceutical Group Limited Announces NMPA Approves Clinical Trial Application in China for Global Innovative Radionuclide-Drug Conjugate TLX591-CDx

Grand Pharmaceutical Group Limited Announces Clinical Trial Application in China for Global Innovative Radionuclide-Drug Conjugate TLX250-CDX Approved by NMPA

Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 43% Discount?

Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly

First half 2022 earnings released

Grand Pharmaceutical Group Limited Provides Unaudited Earnings Guidance for Six Months Ended 30 June 2022

Grand Pharmaceutical Group Announces Clinical Trial Applications in China for Global Innovative Radionuclide-Drug Conjugates TLX591-CDX AND TLX250-CDX Accepted by NMPA

Grand Pharmaceutical Group Limited to Report First Half, 2022 Results on Aug 10, 2022

Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching